Targeting lysine methyltransferase 2C deficiency: New frontiers in breast cancer therapy and prognosis

Area of Science:

• Oncology
• Molecular Biology
• Epigenetics

Background:

• Loss-of-function mutations in lysine methyltransferase 2 (KMT2C) are common in breast cancer.
• KMT2C mutations correlate with increased tumor heterogeneity, aggressive behavior, and poor prognosis.
• The exact mechanisms by which KMT2C deficiency drives metastasis and therapy resistance are not fully understood.

Purpose of the Study:

• To review the complex roles of KMT2C in breast cancer pathogenesis.
• To highlight KMT2C's interactions with key oncogenic signaling pathways.
• To discuss potential therapeutic strategies for KMT2C-deficient breast cancers.

Main Methods:

• Comprehensive literature review of KMT2C's functions in breast cancer.
• Analysis of KMT2C's interplay with signaling networks like IFNγ-EMT/MET, MAPK/ERK, and PI3K/AKT/mTOR.
• Examination of KMT2C's interaction with the KDM6A-MMP3 regulatory circuit.

Main Results:

• KMT2C deficiency influences critical oncogenic signaling networks.
• KMT2C interacts with pathways including IFNγ-EMT/MET, MAPK/ERK, PI3K/AKT/mTOR, and KDM6A-MMP3.
• These interactions contribute to tumor progression and therapeutic challenges.

Conclusions:

• KMT2C plays a crucial role as a tumor suppressor in breast cancer.
• Understanding KMT2C's molecular mechanisms provides rationale for targeted therapies.
• Precision therapies targeting KMT2C-mutant tumors are a promising avenue.